Dr. Edd Fleming is the Executive Vice President of Enavate Sciences where he invests in and supports therapeutic companies. In 2022, Edd retired as Senior Partner at McKinsey & Company where he worked extensively with both large and small biopharmaceutical companies on their strategic and operational priorities. He was the global leader of McKinsey’s R&D practice where he was responsible for its client service and knowledge development on R&D topics. Edd earned his B.A. in Chemistry from Harvard University, his M.D. from Vanderbilt University, and completed internal medicine training at Johns Hopkins Hospital and subspecialty training in pulmonary and critical care medicine at the University of California, San Francisco. Edd serves on the Boards of CRISPR Therapeutics, Komodo Health, Upstream Bio, OrsoBio and the Board of Visitors for Vanderbilt’s School of Basic Sciences.